Quick Answer
ELITE PHARMACEUTICALS INC /NV/ reported Total Revenue of $84.04 million for the year ending 2025.
- ELITE PHARMACEUTICALS INC /NV/ showed an increase of +48.4% in Total Revenue from 2024 to 2025.
- This data is from ELITE PHARMACEUTICALS INC /NV/'s annual report (Form 10-K), filed with the SEC on June 30, 2025.
- XBRL data for this metric is available from 2018 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $1.70 million | Q3 2017: $1.62 million | Q4 2017: $2.54 million | Q2 2018: $2.17 million | Q3 2018: $1.36 million | Q4 2018: $2.69 million | Q2 2019: $3.36 million | Q3 2019: $4.63 million | Q4 2019: $5.06 million | Q2 2020: $7.54 million | Q2 2020: $7.54 million | Q3 2020: $7.40 million | Q3 2020: $7.40 million | Q4 2020: $6.05 million | Q4 2020: $6.05 million | Q2 2021: $7.06 million | Q3 2021: $8.56 million | Q4 2021: $8.97 million | Q2 2022: $7.67 million | Q3 2022: $8.59 million | Q4 2022: $9.25 million | Q2 2023: $8.98 million | Q3 2023: $14.16 million | Q4 2023: $15.54 million | Q2 2024: $18.80 million | Q3 2024: $18.88 million | Q4 2024: $14.36 million | Q2 2025: $40.21 million | Q3 2025: $36.32 million | Q4 2025: $31.59 million.
- Over the full 9 years of available data (2018 to 2025), ELITE PHARMACEUTICALS INC /NV/'s Total Revenue has grown by 1,026.8%.
- Historical annual values: Fiscal year 2025: $84.04 million | Fiscal year 2024: $56.63 million | Fiscal year 2023: $34.16 million | Fiscal year 2022: $32.26 million | Fiscal year 2021: $25.38 million | Fiscal year 2021: $25.38 million | Fiscal year 2020: $17.99 million | Fiscal year 2019: $7.57 million | Fiscal year 2018: $7.46 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: